NCI Grants Establish 18 Biomarkers Developmental Laboratories

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

BETHESDA, Md-Nearly $8 million in grants will help 17 organizations establish 18 Biomarkers Developmental Laboratories, part of the National Cancer Institute’s new Early Detection Research Network. The laboratories are charged with identifying, characterizing, and refining techniques for finding molecular, genetic, and biologic biomarkers.

BETHESDA, Md—Nearly $8 million in grants will help 17 organizations establish 18 Biomarkers Developmental Laboratories, part of the National Cancer Institute’s new Early Detection Research Network. The laboratories are charged with identifying, characterizing, and refining techniques for finding molecular, genetic, and biologic biomarkers.

Two laboratories will be established at the University of Maryland School of Medicine. Other grants went to the University of Colorado, Yale University, Lombardi Cancer Center, the University of South Florida, Northwestern University, Johns Hopkins University, the University of Michigan, Genetica, Inc. (Cold Spring, NY), Mount Sinai School of Medicine, Duke Medical Center, Thomas Jefferson University, the University of Pittsburgh, M.D. Anderson Cancer Center, University of Texas Southwestern Medical Center (Dallas), Eastern Virginia Medical School, and the University of Washington.

Articles in this issue
SWOG to Study Docetaxel/Estramustine in Advanced Prostate Cancer
US Smoking Rates No Longer Falling, Due to More Young Smokers
Americans Favor Higher Cigarette Tax to Balance the Budget
Saint Vincents Hospital Opens Comprehensive Cancer Center
New Breast Biopsy Techniques Allow ‘One-Stop’ Procedures
Director of NCI Mentioned as a Candidate to Head NIH
Challenges in Designing Chemoprevention Trials
Black Women Underrepresented in Breast Cancer Trials
UnitedHealthcare Plan Gives Physicians Final Say on Care
New Agents, Sequential Schedules Hold Promise
Half-Day Workshop Can Improve Cancer Team’s Communication Skills
The Search for Better SERMs Continues
Four SPORE Grants Will Support Ovarian Cancer Research
$70 Million Will Fund Tobacco Study Centers at Seven Universities
Cancer Risk of Veterans Exposed to Nuclear Weapons Tests Unresolved
Related Videos
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
Experts on MM
A panel of 4 experts on multiple myeloma seated at a long table
Marwan G. Fakih, MD, an expert on colorectal cancer
Experts on MM
Related Content
EU's CHMP Recommends Subcutaneous Atezolizumab Approval in Multiple Cancers

EU's CHMP Recommends Subcutaneous Atezolizumab Approval in Multiple Cancers

November 28th 2023
Article

Data from the phase 1b/3 IMscin001 trial support the Committee for Medicinal Products for Human Use’s positive opinion on subcutaneous atezolizumab in lung cancer and other disease types.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.

Belantamab Mafodotin Improves PFS in Relapsed/Refractory Multiple Myeloma

November 28th 2023
Article

Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.

New treatment updates could help find more patient subtypes to target and treat in the world of CRC.

Multidisciplinary Care and New Treatment Options in CRC

November 20th 2023
Podcast

New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.

Safety data from the phase 3 PREVAPIX-ALL trial support the use of apixaban among pediatric patients with acute lymphoblastic leukemia who are at high risk of thrombosis.

Apixaban Yields No Significant Benefit in Acute Lymphoblastic Leukemia

November 27th 2023
Article

Safety data from the phase 3 PREVAPIX-ALL trial support the use of apixaban among pediatric patients with acute lymphoblastic leukemia who are at high risk of thrombosis.

Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.

Frontline Advanced Endometrial Cancer Therapy Confers High Economic Burden

November 27th 2023
Article

Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.